Results 61 to 70 of about 1,204 (125)

The utilization of efgartigimod in the treatment of acute cerebellar ataxia: a case report

Frontiers in Immunology
BackgroundAcute cerebellar ataxia (ACA) is the most common cause of acute ataxia in children and adolescents. It is a cerebellar disorder with multifactorial pathogenesis, often triggered by viral or bacterial infections, as well as autoimmune mechanisms.
Liu L. Yang, Yushuang Ruan, Fucheng Cai, Yuanpeng Xia   +3 more
doaj   +1 more source

Sequential administration of efgartigimod shortened the course of Guillain–Barré syndrome: a case series

Therapeutic Advances in Neurological Disorders
Guillain–Barré syndrome (GBS) is a serious neurological condition with limited treatment options. A recent report demonstrated successful treatment with efgartigimod alone in two patients with GBS, although it did not significantly shorten the disease ...
Sihui Chen, Ruwei Ou, Qianqian Wei, Bi Zhao, Xueping Chen   +4 more
doaj   +1 more source

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series

Frontiers in Immunology
The coexistence of myasthenia gravis (MG) with other IgG-mediated autoimmune diseases represents a clinically heterogeneous condition, driven by pathogenic autoantibodies.
Yunjia Li, Yunjia Li, Yunjia Li, Yingying Yang, Yingying Yang, Yingying Yang, Ying Zhu, Ying Zhu, Ying Zhu, Ruixia Zhu, Ruixia Zhu, Ruixia Zhu   +11 more
doaj   +1 more source

Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP

Platelets
Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, represents a novel therapeutic approach for refractory immune thrombocytopenia (ITP). However, its clinical positioning and durability of response in real-world settings remain unclear.
Fumiya Wada, Hiroyuki Matsui, Takuji Nakamura, Tomomi Satoh-Nakamura, Yutaka Shinkawa, Hisanori Umehara, Akifumi Takaori-Kondo   +6 more
doaj   +1 more source

Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes

Therapeutic Advances in Neurological Disorders
Background: Efgartigimod is an approved biologic for generalized myasthenia gravis (gMG), which is an autoimmune disease and can potentially be life-threatening. However, the therapeutic response to efgartigimod among the acetylcholine receptor gMG (AChR-
Lei Jin, Zhangyu Zou, Qinzhou Wang, Wenshuang Zeng, Qilong Jiang, Jing Chen, Jianquan Shi, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Yaoxian Yue, Zhouao Zhang, Yong Zhang, Xiuming Guo, Lei Du, Zhongyan Zhao, Shixiong Huang, Ying Chen, Zongtai Wu, Chong Yan, Jianying Xi, Jie Song, Sushan Luo, Chongbo Zhao   +24 more
doaj   +1 more source

Transitioning from efgartigimod to tacrolimus in chronic inflammatory demyelinating polyneuropathy: a prospective case series

Frontiers in Immunology
To describe the clinical outcomes of transitioning from efgartigimod to tacrolimus in chronic inflammatory demyelinating polyneuropathy (CIDP) patients.
Yujia Shen, Yujia Shen, Yujia Shen, Jianian Hu, Jianian Hu, Jianian Hu, Chong Sun, Chong Sun, Chong Sun, Yiyun Huang, Yiyun Huang, Yiyun Huang, Heting Cai, Heting Cai, Heting Cai, Kuan Liu, Kuan Liu, Kuan Liu, Xinyue Huang, Xinyue Huang, Xinyue Huang, Jian Sun, Jian Sun, Jian Sun, Yanyin Zhao, Yanyin Zhao, Yanyin Zhao, Chongbo Zhao, Chongbo Zhao, Chongbo Zhao, Jie Lin, Jie Lin, Jie Lin   +32 more
doaj   +1 more source

Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report

BMC Neurology
Background Guillain-Barré syndrome (GBS) is a peripheral neuropathy mediated by immunoglobulin G (IgG) autoantibodies, which can cause acute flaccid paralysis. Miller-Fisher syndrome (MFS) is a variant of GBS, and in some cases, MFS may overlap with GBS (
Bai Qi Hu, Sen Xiang Wu, Qiao Wen Tong, Hua Ye, Ping Ping Jin   +4 more
doaj   +1 more source

Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis

Neurology and Therapy
Myasthenic crisis (MC) is a potentially fatal complication of myasthenia gravis (MG), often requiring intensive care and rescue therapies such as intravenous immunoglobulin (IVIG) and corticosteroids.
Nicasio Rini, Flora D’Amico, Valentina Portera, Filippo Brighina, Vincenzo Di Stefano   +4 more
doaj   +1 more source

Case Report: A Patient with Lambert-Eaton Myasthenic Syndrome Successfully Treated with Efgartigimod

International Medical Case Reports Journal
Lizhu Han,1,2 Jili Shen,3 Jie Wei,3 Yue Zhang2 1Department of Neurology, Anhui No.2 Provincial People’s Hospital, Hefei, Anhui, People’s Republic of China; 2Department of Neurology, National Center for Neurological Disorders, Huashan Rare Disease Centre,
Han L, Shen J, Wei J, Zhang Y
doaj  

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod. [PDF]

J Neurol Neurosurg Psychiatry
Khani-Habibabadi F, Verhamme FM, Moshir M, Casneuf T, Rao VTS, Steeland S, Ulrichts P, Pham MC, Nowak RJ, Roy B, O'Connor KC.   +10 more
europepmc   +1 more source